Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Dr. Triparna Sen as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment.
SCLC transformation is a common resistance mechanism for multiple types of NSCLC, including EGFR, ALK, and RET. Hosted by Dr. Amy Moore, LUNGevity’s VP of Global Engagements and Patient Partnerships. Dr. Sen is Co-Director of the Lung Cancer PDX Platform at the Center for Thoracic Oncology at the Icahn School of Medicine at Mount Sinai in New York. Watch video here.